Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

BACKGROUND: Bevacizumab and temsirolimus are active agents in advanced solid tumors. Temsirolimus inhibits mTOR in the PI3 kinase/AKT/mTOR pathway as well as CYP2A, which may be a resistance mechanism for cetuximab. In addition, temsirolimus attenuates upregulation of HIF-1α levels, which may be a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029622/
https://www.ncbi.nlm.nih.gov/pubmed/26933802
http://dx.doi.org/10.18632/oncotarget.7594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029622/
https://www.ncbi.nlm.nih.gov/pubmed/26933802
http://dx.doi.org/10.18632/oncotarget.7594

Ejemplares similares